Cargando…
An isogenic cell line panel for sequence-based screening of targeted anticancer drugs
We describe the creation of an isogenic cell line panel representing common cancer pathways, with features optimized for high-throughput screening. More than 1,800 cell lines from three normal human cell lines were generated using CRISPR technologies. Surprisingly, most of these lines did not result...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184558/ https://www.ncbi.nlm.nih.gov/pubmed/35692635 http://dx.doi.org/10.1016/j.isci.2022.104437 |
_version_ | 1784724548135944192 |
---|---|
author | Cook, Ashley L. Wyhs, Nicolas Sur, Surojit Ptak, Blair Popoli, Maria Dobbyn, Laura Papadopoulos, Tasos Bettegowda, Chetan Papadopoulos, Nickolas Vogelstein, Bert Zhou, Shibin Kinzler, Kenneth W. |
author_facet | Cook, Ashley L. Wyhs, Nicolas Sur, Surojit Ptak, Blair Popoli, Maria Dobbyn, Laura Papadopoulos, Tasos Bettegowda, Chetan Papadopoulos, Nickolas Vogelstein, Bert Zhou, Shibin Kinzler, Kenneth W. |
author_sort | Cook, Ashley L. |
collection | PubMed |
description | We describe the creation of an isogenic cell line panel representing common cancer pathways, with features optimized for high-throughput screening. More than 1,800 cell lines from three normal human cell lines were generated using CRISPR technologies. Surprisingly, most of these lines did not result in complete gene inactivation despite integration of sgRNA at the desired genomic site. A subset of the lines harbored biallelic disruptions of the targeted tumor suppressor gene, yielding a final panel of 100 well-characterized lines covering 19 frequently lost cancer pathways. This panel included genetic markers optimized for sequence-based ratiometric assays for drug-based screening assays. To illustrate the potential utility of this panel, we developed a high-throughput screen that identified Wee1 inhibitor MK-1775 as a selective growth inhibitor of cells with inactivation of TP53. These cell lines and screening approach should prove useful for researchers studying a variety of cellular and biochemical phenomena. |
format | Online Article Text |
id | pubmed-9184558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-91845582022-06-11 An isogenic cell line panel for sequence-based screening of targeted anticancer drugs Cook, Ashley L. Wyhs, Nicolas Sur, Surojit Ptak, Blair Popoli, Maria Dobbyn, Laura Papadopoulos, Tasos Bettegowda, Chetan Papadopoulos, Nickolas Vogelstein, Bert Zhou, Shibin Kinzler, Kenneth W. iScience Article We describe the creation of an isogenic cell line panel representing common cancer pathways, with features optimized for high-throughput screening. More than 1,800 cell lines from three normal human cell lines were generated using CRISPR technologies. Surprisingly, most of these lines did not result in complete gene inactivation despite integration of sgRNA at the desired genomic site. A subset of the lines harbored biallelic disruptions of the targeted tumor suppressor gene, yielding a final panel of 100 well-characterized lines covering 19 frequently lost cancer pathways. This panel included genetic markers optimized for sequence-based ratiometric assays for drug-based screening assays. To illustrate the potential utility of this panel, we developed a high-throughput screen that identified Wee1 inhibitor MK-1775 as a selective growth inhibitor of cells with inactivation of TP53. These cell lines and screening approach should prove useful for researchers studying a variety of cellular and biochemical phenomena. Elsevier 2022-05-23 /pmc/articles/PMC9184558/ /pubmed/35692635 http://dx.doi.org/10.1016/j.isci.2022.104437 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cook, Ashley L. Wyhs, Nicolas Sur, Surojit Ptak, Blair Popoli, Maria Dobbyn, Laura Papadopoulos, Tasos Bettegowda, Chetan Papadopoulos, Nickolas Vogelstein, Bert Zhou, Shibin Kinzler, Kenneth W. An isogenic cell line panel for sequence-based screening of targeted anticancer drugs |
title | An isogenic cell line panel for sequence-based screening of targeted anticancer drugs |
title_full | An isogenic cell line panel for sequence-based screening of targeted anticancer drugs |
title_fullStr | An isogenic cell line panel for sequence-based screening of targeted anticancer drugs |
title_full_unstemmed | An isogenic cell line panel for sequence-based screening of targeted anticancer drugs |
title_short | An isogenic cell line panel for sequence-based screening of targeted anticancer drugs |
title_sort | isogenic cell line panel for sequence-based screening of targeted anticancer drugs |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184558/ https://www.ncbi.nlm.nih.gov/pubmed/35692635 http://dx.doi.org/10.1016/j.isci.2022.104437 |
work_keys_str_mv | AT cookashleyl anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT wyhsnicolas anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT sursurojit anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT ptakblair anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT popolimaria anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT dobbynlaura anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT papadopoulostasos anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT bettegowdachetan anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT papadopoulosnickolas anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT vogelsteinbert anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT zhoushibin anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT kinzlerkennethw anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT cookashleyl isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT wyhsnicolas isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT sursurojit isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT ptakblair isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT popolimaria isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT dobbynlaura isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT papadopoulostasos isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT bettegowdachetan isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT papadopoulosnickolas isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT vogelsteinbert isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT zhoushibin isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs AT kinzlerkennethw isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs |